DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 214 filers reported holding DENALI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,119,000 | +4.3% | 69,030 | 0.0% | 0.01% | +42.9% |
| Q2 2022 | $2,032,000 | -73.3% | 69,030 | -70.8% | 0.01% | -74.1% |
| Q1 2022 | $7,614,000 | -41.8% | 236,688 | -19.4% | 0.03% | -40.0% |
| Q4 2021 | $13,093,000 | -7.1% | 293,554 | +5.1% | 0.04% | -8.2% |
| Q3 2021 | $14,088,000 | -14.4% | 279,254 | +33.2% | 0.05% | -31.9% |
| Q2 2021 | $16,449,000 | +106.2% | 209,698 | +50.1% | 0.07% | +176.9% |
| Q1 2021 | $7,977,000 | -67.2% | 139,698 | -51.9% | 0.03% | -70.5% |
| Q4 2020 | $24,349,000 | +2515.4% | 290,698 | +1018.6% | 0.09% | +1157.1% |
| Q3 2020 | $931,000 | – | 25,988 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |